Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChimeriVax-JE in Healthy Adults
NCT00981175Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2003
- Primary completion
- Jun 2004
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain at Day 28 and Number of Participants Reporting Injection Site Treatment Emergent Adverse Events. Started Apr 2003; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00981175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981175.